RPG Life Sciences

The drugmaker has more than ₹500 crore of capital available and is evaluating businesses that can add differentiated chemistry, regulatory access and export capabilities

Drug firm RPG Life Sciences is planning to deploy Rs 500 crore over the next 12 months to strengthen its manufacturing and API capabilities through strategic acquisitions. In an interview with PTI, RPG Life Sciences Managing Director Ashok Nair said the company has embarked on a significant expansion phase, backed by a committed capital infusion of Rs 700 crore. "Currently, the acquisitions we have made are to the tune of Rs 200 crore. We are evaluating opportunities that can strengthen our manufacturing footprint. We would like to deploy the Rs 500 crore balance in the next 12 months. We are actively pursuing good assets," Nair said. The company, which operates across domestic and international formulations and Active Pharmaceutical Ingredients (APIs), has set a target of reaching Rs 2,000 crore- 2,500 crore in revenue by 2030. Nair noted that the company started FY27 on a strong footing, recording 16 per cent revenue growth and 18 per cent EBITDA growth in the first quarter. The

Company scouts for USFDA-approved assets; on track for ₹1,000 crore in revenue by FY28

Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.

The board of RPG Life Sciences Technologies has recommended a dividend of ₹24 per equity share, or 300 per cent on the face value of ₹8 per share, fully paid up, for FY26

The scrip declined 10.6 per cent to the day's low of ₹1,880 on the National Stock Exchange (NSE)

The company sharpens its domestic specialty formulations focus and looks to scale APIs through acquisitions, while planning partnership-led GLP-1 launches

Shares of small cap firm RPG Life Sciences surged up to 14.81 per cent, hitting its 52-week high at Rs 2057.15 per share on the BSE in Monday's intraday deals

On the broader market outlook, Vinay Rajani the technical & derivative analyst says that the Nifty needs to breakout from the 18,669 - 18,888 range to gain momentum.

RPG Life Sciences said its net profit increased 14 per cent to Rs 14.63 crore for the third quarter ended December 31, 2021.

The domestic formulations business of the company will continue to focus on building chronic therapies, expanding specialty portfolio and life cycle management of current legacy products

Despite the pharmaceutical industry having the essential commodities tag, the administration, police and building societies was not allowing movement of people and products

Meanwhile, operational revenue during the quarter grew 8.8 per cent at Rs 98.49 crore, as against Rs 90.5 crore in the corresponding quarter of the previous year.

Pharma company to enter US market in two-three years

The company is diversifying in new areas such as cosmetology and dermatology

The stock surged 17% to Rs 273 on the BSE on back of heavy volumes.

The formulations business contributes about 60 per cent to company's overall sales